Search hospitals
>
British Columbia
>
VANCOUVER
St Paul's Hospital
Claim this profile
VANCOUVER, British Columbia V6Z 1Y6
Global Leader in Heart Failure
Global Leader in Von Willebrand Disease
Conducts research for Cardiovascular Disease
Conducts research for Idiopathic Pulmonary Fibrosis
Conducts research for Heart Attack
312 reported clinical trials
31 medical researchers
Summary
St Paul's Hospital is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Heart Failure, Von Willebrand Disease, Cardiovascular Disease, Idiopathic Pulmonary Fibrosis, Heart Attack and other specialties. St Paul's Hospital is involved with conducting 312 clinical trials across 543 conditions. There are 31 research doctors associated with this hospital, such as John Webb, MD, Robert Boone, MD, Brian Clarke, MD, and Mustafa Toma, MD.
Area of expertise
Heart Failure
St Paul's Hospital has run 24 trials for Heart Failure. Some of their research focus areas include:
Von Willebrand Disease
St Paul's Hospital has run 18 trials for Von Willebrand Disease.
Top PIs
John Webb, MD
Providence Health - St. Paul's Hospital
7 years of reported clinical research
Robert Boone, MD
St. Paul's Hospital
7 years of reported clinical research
Brian Clarke, MD
University of Calbary
3 years of reported clinical research
Mustafa Toma, MD
St. Paul's Hospital
7 years of reported clinical research
Clinical Trials running at St Paul's Hospital
Heart Failure
Idiopathic Pulmonary Fibrosis
Spinal Cord Injury
Von Willebrand Disease
Sarcoidosis
Chronic Renal Failure
Tricuspid Regurgitation
Cardiovascular Disease
Aortic Stenosis
Atrial Fibrillation
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting
1 award
Phase 3
Ziltivekimab
for Heart Failure
This trial is testing ziltivekimab to see if it can help people with heart failure and inflammation by reducing inflammation and improving heart function.
Recruiting
1 award
Phase 3
7 criteria
Omecamtiv Mecarbil
for Heart Failure
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Recruiting
1 award
Phase 3
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at St Paul's Hospital?
St Paul's Hospital is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Heart Failure, Von Willebrand Disease, Cardiovascular Disease, Idiopathic Pulmonary Fibrosis, Heart Attack and other specialties. St Paul's Hospital is involved with conducting 312 clinical trials across 543 conditions. There are 31 research doctors associated with this hospital, such as John Webb, MD, Robert Boone, MD, Brian Clarke, MD, and Mustafa Toma, MD.
Where is St Paul's Hospital located?
St. Paul's Hospital is situated at 1081 Burrard St, Vancouver, BC V6Z 1Y6. Pedestrian access is provided off Burrard Street and Comox Street. Vehicle drop-offs are designated at the Comox Street Entrance.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at St. Paul's Hospital, contact Providence's financial counselors at 855-229-6466, available Monday to Friday, 7 a.m. to 5:30 p.m. For more detailed contact information and assistance options, visit their contact resources directory.
What insurance does St Paul's Hospital accept?
St. Paul's Hospital, situated in downtown Vancouver, highlights the necessity of carrying supplementary insurance coverage for overnight stays. Patients are advised to confirm appointments and adhere to pre-surgery instructions, including securing authorization or referrals from primary care physicians. For specifics on accepted insurance plans, contacting St. Paul's Hospital directly is recommended.
What awards or recognition has St Paul's Hospital received?
St. Paul's Hospital, located in Vancouver, British Columbia, is celebrated for its transformative patient care and significant health outcomes improvements regionally and globally. It has achieved recognition as a world-leading research institution, notably for converting HIV into a manageable chronic condition, pioneering minimally-invasive heart valve replacements, and establishing specialized mental health programs for youth.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.